Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18045482 | 0.92 | HSD17B2 (0.51) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL703602 | 0.79 | CA12 (0.64) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL1011945 | 0.77 | HSD17B2 (0.61) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL1660365 | 0.77 | HSD17B2 (0.76) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL30506315 | 0.77 | HSD17B2 (0.76) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL11758670 | 0.76 | TDP1 (0.57) | LMNACA12CA1CA2CA7 | |
| SCHEMBL31096065 | 0.75 | HSD17B2 (0.64) | HSD17B2LMNAMAPTTSHRNPC1 | |
| SCHEMBL3372010 | 0.73 | HSD17B2 (0.61) | HSD17B2LMNAMAPTTSHRNPC1 | |
| SCHEMBL310621 | 0.73 | TSHR (0.71) | HSD17B2LMNACA12CA1CA2 | |
| SCHEMBL31474384 | 0.73 | TSHR (0.71) | HSD17B2LMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296689-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-8883843-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130345282-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8404737-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120252864-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2012-10-04 | — | — | US | disclosed |
| US-8124646-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124646-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345282-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | HSD17B2 1755/4885LMNA 3947/4885CA12 4238/4885 |
| US-20120252864-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | HSD17B2 1755/4885LMNA 3947/4885CA12 4238/4885 |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | HSD17B2 1755/4885LMNA 3947/4885CA12 4238/4885 |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | HSD17B2 1755/4885LMNA 3947/4885CA12 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.